Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03793348

Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles

Study evaluating the efficacy of a micro coring device for the treatment of moderate to severe check wrinkles

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Wrinkle Congenital, Hereditary, and Neonatal Diseases and Abnormalities Connective Tissue Diseases Cutis Laxa Genetic Diseases, Inborn Skin Diseases Skin Diseases, Genetic Skin and Connective Tissue Diseases

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Laser and Skin Surgery Center of Northern California, Sacramento, California, United States

Loading trial locations.

About this study

Up to 35 subjects who meet the inclusion/exclusion criteria will be treated. All subjects will be monitored for a period of 90 days post treatment.

Study results will be assessed with the following:

  • Lemperle Scale
  • Investigator GAIS Scale
  • Subject Satisfaction Scale

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females 40-70 years of age
  • Fitzpatrick Skin Type I to IV as judged by the Investigator
  • Cheek areas are at least a score of 3 using the Lemperle Wrinkle Assessment Scale as judged by the Investigator
  • Able to provide written informed consent, understand and willing to comply with all study related procedures and follow-up visits.

Exclusion criteria

  • Lesions suspicious for any malignancy or the presence of actinic keratosis, melasma, vitiligo, cutaneous papules/nodules or active inflammatory lesions in the areas to be treated
  • History of keloid formation or hypertrophic scarring
  • History of trauma or surgery to the treatment areas in the past 6 months
  • Scar present in the areas to be treated
  • Silicone injections in the areas to be treated
  • Injection of dermal fillers, fat or botulinum toxin, as well as any minimally invasive/invasive medical device for skin treatment, in the study treatment areas, within the past 6 months (i.e., dermabrasion, laser, RF devices)
  • Active smokers (0.5 pack/day) or having quit within 3 months prior to treatment
  • Active, chronic, or recurrent infection
  • History of compromised immune system or currently being treated with immunosuppressive agents
  • History of sensitivity to analgesic agents, Aquaphor®, topical or local anesthetics (e.g., lidocaine, benzocaine, procaine) or chlorhexidine, povidone-iodine or epinephrine
  • Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior to treatment
  • Treatment with aspirin or other blood thinning agents within 14 days prior to treatment
  • History or presence of any clinically significant bleeding disorder
  • Any issue that, at the discretion of the Investigator, would interfere with assessment of safety or efficacy or compromise the subject's ability to participate in the study
  • Treatment with an investigational device or agent within 30 days before treatment or during the study period

Treatment and study plan

MCD

Device

Micro coring skin removal with automated coring device

Primary outcomes

  1. Assess level of wrinkle improvement using the Lemperle Wrinkle Severity Scale

    Time frame: 90 day post treatment

    A mean change of 1 point or greater reduction in cheek wrinkle severity at 90 days post treatment using the Lemperle Wrinkle Severity Scale, as assessed by (3) blinded Independent Reviewers Lemperle Scale:

    No wrinkles =0 Just perceptible wrinkles =1 Shallow wrinkles=2 Moderately deep wrinkles=3 Deep wrinkles, well-defined edges =4 Very deep wrinkles, redundant fold=5

Secondary outcomes

  1. Assess aesthetic improvement using Global Aesthetic Improvement Scale

    Time frame: 90 day post treatment

    Overall aesthetic improvement level per Principal Investigator at 90 days compared to baseline on the Global Aesthetic Improvement Scale.

    Very Much Improved (Optimal cosmetic result)=3 Much Improved (Marked improvement from the initial condition, but not completely optimal)=2 No Change (The appearance is essentially the same as baseline)=0 Worse (The appearance is worse than the original condition)= -1 Much Worse (Marked worsening in appearance from the initial condition)= - 2 Very Much Worse (Obvious worsening in appearance from the initial condition)=- 3

  2. Assess aesthetic improvement using Subject Satisfaction Scale

    Time frame: 90 day post treatment

    Satisfaction with the aesthetic appearance of the treatment area per Subject Satisfaction Scale compared to baseline.

    Extremely dissatisfied=0 Somewhat dissatisfied=1 Slightly dissatisfied=2 Neither satisfied or dissatisfied=3 Slightly satisfied=4 Somewhat satisfied=5 Extremely satisfied=6

  3. Assess aesthetic improvement in wrinkles using OCT images (optional)

    Time frame: Baseline to Day 90 post treatment

    Assessment of improvement using OCT images with Vista software to determine wrinkle depth reduction, comparing pre-treatment depth to post treatment depth.

  4. Assess efficacy results using Canfield Software,, by comparing the changes in wrinkles at baseline and 90 days post treatment.

    Time frame: Baseline to Day 90 post treatment

    Validated Canfield software comparing baseline wrinkles to day 90 follow up wrinkles via automated photo analysis.

  5. Assess safety profile by recording of adverse events

    Time frame: Adverse events will be recorded immediately treatment, Day 1, Day 7, Day 30, Day 60 and Day 90 post treatment. Ad hoc assessment can occur upon subject report of AE.

    The incidence and severity of systemic and local adverse events will be recorded by the PI at all visits and a 14 day diary completed by each subject will also be collected.

  6. Assess safety profile by reviewing completed 14 day subject diary for potential side effects.

    Time frame: For 14 days post treatment

    14 day diary completed by each subject will record potential side effects, level of severity (mild = 1; moderate = 2; severe = 3), and end date of the potential side effects.

Sponsors and collaborators

Lead sponsor

Cytrellis Biosystems, Inc.

Industry

Registry information

Official study title

A Prospective, Multi-center, Pivotal Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jan 4, 2019
Registry last updated
Jan 4, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.